Semax is a synthetic heptapeptide derived from the ACTH(4-7) fragment, studied extensively in preclinical and laboratory models for its influence on central nervous system signaling. Originally developed in Russia, Semax research has focused on its capacity to modulate brain-derived neurotrophic factor (BDNF) expression, dopamine and serotonin turnover, and neuroprotective cascades — making it one of the most investigated nootropic peptides in modern peptide science. The 10MG format is widely used in laboratory settings where researchers require a concentrated, stable supply for in vitro and in vivo experimental protocols.
Across decades of research, Semax has been explored as a model compound for understanding how short-chain ACTH analogs influence neuroplasticity, cognitive signaling, and stress-resilience pathways. Studies have investigated its uptake via intranasal delivery models, its downstream effects on gene expression, and its potential interactions with enkephalinase inhibition — positioning it as a compelling subject across neuroscience, cognitive biology, and neuroprotection research domains.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. Semax is not approved for human therapeutic use outside specific jurisdictions. All references to effects describe findings from preclinical models and published research literature only.
Semax - 5MG — Research-Grade Reference Material Semax - 5MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
Ara-290 10MG
$45.00$33.75 with 1st order
Epithalon - 10MG
$50.00$37.50 with 1st order
GLP-3 (R) 60MG
$275.00$206.25 with 1st order
Frequently Asked Questions
What is Semax and how is it structurally derived?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, derived from the adrenocorticotropic hormone (ACTH) fragment 4–7. Unlike ACTH itself, Semax does not activate adrenal steroidogenesis, as it lacks the C-terminal sequence responsible for corticosteroid stimulation. Research has focused on its neuroactive properties in isolation from classical ACTH endocrine effects.
What signaling pathways does Semax research focus on?
The primary research focus involves Semax’s modulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression. Studies have also investigated its effects on serotonin and dopamine systems, enkephalinase inhibition, and anti-inflammatory cytokine signaling in neural tissue models.
Why is intranasal delivery used in Semax research models?
Intranasal delivery has been studied as a route that may facilitate direct transport along the olfactory pathway to the central nervous system, potentially bypassing blood-brain barrier limitations. Research models using nasal administration have investigated Semax concentrations in cerebrospinal fluid and brain tissue relative to systemic circulation.
What does research suggest about Semax and BDNF expression?
Multiple preclinical studies have investigated Semax’s capacity to upregulate BDNF mRNA and protein expression in hippocampal and cortical tissue. BDNF plays a key role in synaptic plasticity, long-term potentiation, and neuronal survival — making this pathway a central focus of Semax neuroprotection research.
How does Semax compare to Selank in research models?
While both are Russian-developed synthetic peptides studied for CNS effects, Semax research emphasizes BDNF/ACTH-analog activity and cognitive enhancement signaling, while Selank research focuses more heavily on GABAergic modulation and anxiolytic-like effects. Some researchers study them in combination for complementary mechanisms. The Selank vs Semax comparison provides a detailed mechanistic breakdown.
What is the significance of Semax’s enkephalinase inhibition in research?
Studies have suggested that Semax may inhibit enkephalinase (neprilysin), the enzyme responsible for breaking down endogenous enkephalins. This could prolong the activity of endogenous opioid peptides in synaptic clefts, contributing to the analgesic and mood-related signaling observed in some animal model studies.
What formats are available for Semax in research supply?
Semax is available in lyophilized powder form (such as the 5MG and 10MG formats) as well as nasal spray preparations at 5MG and 10MG concentrations. Researchers typically select the format based on the delivery route being investigated in their specific experimental protocols.
Is Semax studied for neuroprotection in ischemia models?
Yes. Several studies using rodent ischemia models have investigated Semax’s effects on infarct volume, neuronal survival markers, and recovery of motor function following experimental cerebral ischemia events. These are strictly preclinical findings in controlled laboratory settings.
Structural Profile & Biochemical Identity of Semax
Semax carries the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro, representing an analog of the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro extension that has been shown in research to significantly extend its biological stability compared to the parent fragment. This modification reduces susceptibility to proteolytic degradation, a critical property for laboratory research involving in vivo rodent models where peptide half-life directly impacts experimental design and dosing interval calculations.
Semax - 5MG — Research-Grade Reference Material Semax - 5MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
Ara-290 10MG
$45.00$33.75 with 1st order
Epithalon - 10MG
$50.00$37.50 with 1st order
GLP-3 (R) 60MG
$275.00$206.25 with 1st order
The molecular weight of Semax is approximately 887.0 Da, and it is typically supplied as a white lyophilized powder with high water solubility — a favorable characteristic for reconstitution in aqueous vehicles used in intranasal, subcutaneous, and in vitro delivery protocols. Its stability in solution is an active area of characterization for researchers designing long-duration studies.
Relationship to ACTH and Melanocortin Receptors
Despite its ACTH origin, Semax’s primary research interest lies outside classical melanocortin receptor (MCR) signaling. While the parent ACTH molecule activates MC1R through MC5R, the short fragment used in Semax construction lacks full receptor binding capacity for adrenal stimulation. Research has instead focused on indirect neuromodulatory mechanisms — particularly those involving BDNF, NGF, and monoamine neurotransmitter systems — rather than direct MCR agonism. This distinguishes Semax mechanistically from compounds like PT-141, which operates through direct melanocortin signaling pathways.
Semax 5MG for laboratory research →
BDNF Signaling: The Core Mechanism in Semax Research
Brain-derived neurotrophic factor is among the most studied neurotrophins in neuroscience, with roles spanning synaptic plasticity, long-term potentiation (LTP), neuronal survival, and adult neurogenesis. Research into Semax has consistently returned to BDNF upregulation as a central mechanism of interest. Studies using rat hippocampal preparations have reported increases in BDNF mRNA expression following Semax administration, with effects detectable in both the hippocampus and frontal cortex — brain regions associated with learning and memory consolidation.
TrkB Receptor Cascade Implications
BDNF exerts its effects primarily through tropomyosin receptor kinase B (TrkB), triggering downstream signaling through the MAPK/ERK pathway, PI3K/Akt, and PLCγ — cascades associated with neuronal differentiation, anti-apoptotic signaling, and synaptic strengthening. Research models exploring Semax-induced BDNF upregulation are therefore simultaneously investigating potential downstream effects across all of these pathways, making Semax a broad research tool for neuroplasticity studies rather than a narrow mechanistic probe.
NGF and Neurotrophin Crosstalk
Alongside BDNF, nerve growth factor (NGF) has been identified as another neurotrophin potentially influenced by Semax in animal model studies. NGF is critical for the maintenance of cholinergic neurons in the basal forebrain — a population of cells heavily implicated in attentional and memory circuitry. The dual modulation of BDNF and NGF in preclinical research positions Semax as a compound of interest for models of age-related cognitive decline and cholinergic dysfunction, areas that nootropic peptide research continues to actively explore.
Semax 10MG Nasal Spray for research →
Monoamine Neurotransmitter Effects in Preclinical Studies
Beyond neurotrophic signaling, research has investigated how Semax interacts with classical monoamine systems. Animal studies have reported measurable changes in serotonin and dopamine turnover in frontal cortical and striatal regions following Semax administration. These findings are of interest to researchers studying attentional regulation, motivation circuitry, and the biological substrates of working memory.
Dopaminergic Pathways
Studies using rodent models have measured alterations in dopamine metabolite ratios (DOPAC/DA and HVA/DA) following Semax exposure, suggesting increased dopaminergic activity in prefrontal regions. Since dopaminergic tone in the prefrontal cortex is closely tied to executive function and working memory performance in animal cognition paradigms, these findings have attracted significant interest from researchers working in cognitive neuroscience.
Serotonergic Modulation
Serotonin turnover has also been investigated in Semax animal models, with some studies reporting region-specific changes in the limbic system. Given serotonin’s role in mood regulation and stress response, these findings form a basis for exploring Semax in stress-resilience and anxiety-related behavioral paradigms — a research space that also includes Selank, which has been studied extensively for anxiolytic-like mechanisms.
Neuroprotection Research: Ischemia and Oxidative Stress Models
One of the most clinically significant research directions for Semax involves its behavior in models of neurological injury. In rodent ischemia models — particularly middle cerebral artery occlusion (MCAO) protocols — studies have examined Semax’s effects on infarct volume, inflammatory cytokine profiles, and behavioral recovery endpoints. These are strictly preclinical research findings with no established clinical translation, but they represent some of the most robust published data in the Semax literature.
Anti-inflammatory Cytokine Modulation
Research in ischemia models has investigated Semax’s influence on pro-inflammatory cytokines including TNF-α and IL-6, with some studies reporting attenuation of neuroinflammatory cascades in treated animals. The proposed mechanism involves Semax’s capacity to modulate microglial activation states and reduce oxidative stress markers in vulnerable peri-infarct tissue — findings that parallel research directions seen in other neuroprotective peptide classes.
Comparisons to Other Neuroprotective Research Peptides
Within the broader neuroprotective peptide research landscape, Semax occupies an interesting position alongside compounds like Thymosin Alpha-1, which is studied for immune-modulatory and cytoprotective properties, and the GLOW stack compounds studied for tissue-level repair and regenerative signaling. Each targets distinct but occasionally overlapping mechanisms.
Selank & Semax 20MG combination nasal spray for research →
Intranasal Delivery Models in Semax Research
Intranasal peptide delivery has become a major focus in neuroscience research because of the olfactory-trigeminal pathway’s potential to facilitate direct nose-to-brain transport, bypassing hepatic first-pass metabolism and potentially enabling CNS access at lower systemic concentrations. Semax research has particularly leveraged this delivery model, with studies measuring peptide concentrations in cerebrospinal fluid and discrete brain regions following intranasal administration in rodent models.
Researchers studying intranasal bioavailability frequently note Semax as a reference compound due to the substantial body of preclinical data available. The nasal spray format — available at both 5MG and 10MG concentrations — is the most commonly referenced administration route in published research, and aligns with the broader trend toward non-invasive delivery methods explored in cognitive peptide research.
Enkephalinase Inhibition and Extended Signaling Duration
A mechanistically distinctive feature of Semax highlighted in some research papers is its capacity to inhibit enkephalinase (neprilysin/neutral endopeptidase 24.11), an enzyme responsible for the degradation of endogenous enkephalins at synaptic junctions. By attenuating this catabolic enzyme, Semax may extend the bioavailability of endogenous opioid peptides in synaptic clefts — a mechanism that differs substantially from exogenous opioid receptor agonism and represents a more nuanced approach to endogenous neuromodulation in research contexts.
Semax 10MG in Laboratory Research Protocols
The 10MG format of Semax is particularly useful for researchers requiring sufficient material for multi-arm studies, longitudinal in vivo protocols, or parallel in vitro experiments. Typical research applications include:
- BDNF/NGF mRNA and protein expression assays using hippocampal or cortical tissue homogenates
- Behavioral cognition studies utilizing Morris Water Maze, radial arm maze, or novel object recognition paradigms in rodent models
- Neuroinflammation models assessing cytokine profiles (TNF-α, IL-1β, IL-6) in brain tissue following experimental injury
- Comparative monoamine turnover studies using HPLC-EC analysis of dopamine and serotonin metabolites
- Ischemia-reperfusion models investigating infarct volume and neurological deficit scoring
- Intranasal bioavailability studies tracking peptide distribution across CNS compartments
Researchers working across these paradigms frequently reference Semax alongside other nootropic and neuroprotective compounds in comparative frameworks, particularly in the context of Dihexa vs Semax cognitive research comparisons.
Semax 10MG Nasal Spray — research supply →
Where These Fit in Your Research Library
Researchers building a comprehensive nootropic and neuroprotective peptide library will find Semax pairs productively with several complementary compounds:
- Selank — for comparative anxiolytic/GABAergic mechanism studies alongside Semax’s BDNF-focused profile
- Dihexa — for exploring HGF/MET signaling as an alternative neurotrophin axis to Semax’s BDNF pathway
- MOTS-C — for cross-disciplinary research connecting mitochondrial bioenergetics with neurotrophin expression
Selank 10MG Nasal Spray for research →
MOTS-C 10MG Nasal Spray for research →
Final Takeaway: Semax 10MG as a Research Compound
Semax remains one of the most well-documented synthetic neuropeptides in the preclinical research literature, with a mechanistic profile spanning BDNF and NGF upregulation, monoamine neurotransmitter modulation, enkephalinase inhibition, and neuroprotection in ischemia models. Its structural stability, intranasal delivery compatibility, and broad CNS mechanism footprint make the 10MG format a versatile research supply for neuroscience laboratories investigating cognitive signaling, neuroplasticity, and neuroprotective biology.
All research should be conducted within appropriate institutional frameworks, following applicable regulations for peptide research in the relevant jurisdiction. Semax is supplied strictly for in vitro and in vivo laboratory research use only.
Sources & Further Reading
- Dolotov OV et al. — “Semax, an analog of ACTH(4-7) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus” — Brain Research (2006)
- Shadrina MI et al. — “Expression analysis of neuroprotective effect of Semax in middle cerebral artery occlusion” — Journal of Neurochemistry (2010)
- PubMed Search: Semax BDNF Neuroprotection — NIH National Library of Medicine
- PubMed Search: Semax Peptide Cognitive Studies — NIH National Library of Medicine
- Kolomin T et al. — “Semax and Its Influence on Expression of Genes Related to the Immune Response” — Molecular Biology (2013)
